TerminatedPhase 2NCT05009953

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

Studying Adenocarcinoma of the gallbladder and extrahepatic biliary tract

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
CSPC Ouyi Pharmaceutical Co., Ltd.
Principal Investigator
Xiangdong Cheng
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Intervention
Irinotecan Liposome Injection(drug)
Enrollment
17 enrolled
Eligibility
18 years · All sexes
Timeline
20212023

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05009953 on ClinicalTrials.gov

Other trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract

Additional recruiting or active studies for the same condition.

See all trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract

← Back to all trials